



Certificate of Analysis

www.tocris.com

Product Name: Z-VAD-FMK Catalog No.: 2163 Batch No.: 27

CAS Number: 634911-81-9

IUPAC Name: Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: C₂₂H₃₀FN₃O₇

Batch Molecular Weight: 467.49

Physical Appearance: White lyophilised solid

Counter Ion: TFA

Solubility: Soluble to 9.35 mg/ml in DMSO

Storage: Store at -20°C

Peptide Sequence: Z-Val-Ala-DL-Asp(OMe)-FMK

2. ANALYTICAL DATA

HPLC: Shows 96.8% purity

Mass Spectrum: Consistent with structure

3. AMINO ACID ANALYSIS DATA

Amino Acid Theoretical Actual Amino Acid Theoretical Actual

Ala	1.00	1.00	Lys
Arg			Met
Asx			Phe
Cys			Pro
Glx			Ser
Gly			Thr
His			Trp
lle			Tyr
Leu			Val

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

1.00

1.00



Product Information

Print Date: Mar 3rd 2025

www.tocris.com

Product Name: Z-VAD-FMK Catalog No.: 2163 Batch No.: 27

CAS Number: 634911-81-9

IUPAC Name: Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone

Description:

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor. Inhibits caspase processing and apoptosis induction in tumor cells in vitro ($IC_{50} = 0.0015 - 5.8$ mM). Active in vivo.

Physical and Chemical Properties:

Batch Molecular Formula: C₂₂H₃₀FN₃O₇ Batch Molecular Weight: 467.49

Physical Appearance: White lyophilised solid

Peptide Sequence:

Z-Val-Ala-DL-Asp(OMe)-FMK

Storage: Store at -20°C

Solubility & Usage Info:

Soluble to 9.35 mg/ml in DMSO

This product is supplied in lyophilized form. It may appear as a solid, gel or film and be very hard to visualize. Solutions should be made by adding solvent directly to the vial. The vial should then be vortexed vigorously to ensure the product has completely dissolved.

Counter Ion: TFA

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Peptides in solution are much less stable than in lyophilized form. This is especially true for peptides whose sequences contain amino acids such Cys, Met,Trp, Asn, Gln, and N-terminal Glu.

Therefore we recommend storing peptides in solution for as short a time as possible. Avoid repeated freeze thaw cycles by dividing the peptide solution into aliquots and storing the aliquots at -20°C. Any portion of an aliquot unused after thawing should be discarded

Peptides stored in solution can occasionally be susceptible to bacterial degradation. We recommend using sterile solutions or passing the peptide solution through a 0.2 μ m filter to remove potential bacterial contamination whenever possible.

References:

Garcia-Calvo *et al* (1998) Inhibition of human caspases by peptide-based and macromolecular inhibitors. J.Biol.Chem. **273** 32608. PMID: 9829999.

King *et al* (1998) Processing/activation of caspases, -3 and -7 and -8 but not caspase-2, in the induction of apoptosis in B-chronic lyphocytic leukemia cells. Leukemia *12* 1553. PMID: 9766499.

Kunstle *et al* (1997) ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF-α. Immunol.Lett. *55* 5. PMID: 9093874.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use